Promimic AB (PRO) - Net Assets

Latest as of December 2025: Skr59.11 Million SEK ≈ $6.36 Million USD

Based on the latest financial reports, Promimic AB (PRO) has net assets worth Skr59.11 Million SEK (≈ $6.36 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr75.71 Million ≈ $8.15 Million USD) and total liabilities (Skr16.60 Million ≈ $1.79 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PRO financial resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr59.11 Million
% of Total Assets 78.07%
Annual Growth Rate 19.26%
5-Year Change 161.91%
10-Year Change N/A
Growth Volatility 94.51

Promimic AB - Net Assets Trend (2018–2025)

This chart illustrates how Promimic AB's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Promimic AB for the complete picture of this company's asset base.

Annual Net Assets for Promimic AB (2018–2025)

The table below shows the annual net assets of Promimic AB from 2018 to 2025. For live valuation and market cap data, see Promimic AB market capitalisation.

Year Net Assets Change
2025-12-31 Skr59.11 Million
≈ $6.36 Million
-15.46%
2024-12-31 Skr69.91 Million
≈ $7.52 Million
-8.87%
2023-12-31 Skr76.72 Million
≈ $8.26 Million
-5.66%
2022-12-31 Skr81.32 Million
≈ $8.75 Million
+260.32%
2021-12-31 Skr22.57 Million
≈ $2.43 Million
-39.46%
2020-12-31 Skr37.27 Million
≈ $4.01 Million
+43.71%
2019-12-31 Skr25.94 Million
≈ $2.79 Million
+50.61%
2018-12-31 Skr17.22 Million
≈ $1.85 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Promimic AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 8442613000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock Skr1.89 Million 3.20%
Other Components Skr202.87 Million 343.22%
Total Equity Skr59.11 Million 100.00%

Promimic AB Competitors by Market Cap

The table below lists competitors of Promimic AB ranked by their market capitalization.

Company Market Cap
Medivir AB
ST:MVIR
$22.98 Million
CVD Equipment Corporation
NASDAQ:CVV
$22.99 Million
Global Uranium and Enrichment Ltd
AU:GUE
$22.99 Million
Leaders Cosmetics Co. Ltd
KQ:016100
$22.99 Million
Cadence Opportunities Fund Ltd
AU:CDO
$22.97 Million
Xu Yuan Packaging Technology Co Ltd
TWO:8421
$22.94 Million
Dubber Corporation Ltd
AU:DUB
$22.94 Million
Infrared Cameras Holdings Inc
NASDAQ:MSAI
$22.93 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Promimic AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 69,914,000 to 59,107,000, a change of -10,807,000 (-15.5%).
  • Net loss of 8,800,000 reduced equity.
  • Other comprehensive income decreased equity by 487,999.
  • Other factors decreased equity by 1,519,001.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Skr-8.80 Million -14.89%
Other Comprehensive Income Skr-488.00K -0.83%
Other Changes Skr-1.52 Million -2.57%
Total Change Skr- -15.46%

Book Value vs Market Value Analysis

This analysis compares Promimic AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.61x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 11.41x to 3.61x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2018-12-31 Skr0.99 Skr11.30 x
2019-12-31 Skr1.49 Skr11.30 x
2020-12-31 Skr2.16 Skr11.30 x
2021-12-31 Skr1.82 Skr11.30 x
2022-12-31 Skr5.15 Skr11.30 x
2023-12-31 Skr4.15 Skr11.30 x
2024-12-31 Skr3.72 Skr11.30 x
2025-12-31 Skr3.13 Skr11.30 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Promimic AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -14.89%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -19.82%
  • • Asset Turnover: 0.59x
  • • Equity Multiplier: 1.28x
  • Recent ROE (-14.89%) is above the historical average (-37.24%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2018 -87.02% -384.36% 0.16x 1.42x Skr-16.71 Million
2019 -43.55% -196.67% 0.18x 1.26x Skr-13.89 Million
2020 -35.70% -240.83% 0.13x 1.19x Skr-17.18 Million
2021 -67.29% -188.26% 0.25x 1.43x Skr-17.44 Million
2022 -19.54% -97.98% 0.17x 1.14x Skr-24.02 Million
2023 -12.02% -24.88% 0.40x 1.21x Skr-16.89 Million
2024 -17.95% -28.54% 0.50x 1.26x Skr-19.54 Million
2025 -14.89% -19.82% 0.59x 1.28x Skr-14.71 Million

Industry Comparison

This section compares Promimic AB's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $171,567,428
  • Average return on equity (ROE) among peers: -27.92%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Promimic AB (PRO) Skr59.11 Million -87.02% 0.28x $22.97 Million
Acarix A/S (ACARIX) $15.12 Million -127.02% 0.21x $33.84 Million
Arcoma AB (ARCOMA) $48.66 Million 5.27% 0.68x $11.55 Million
Bactiguard Holding AB (publ) (BACTI-B) $387.11 Million -0.84% 0.62x $61.64 Million
BICO Group AB (BICO) $2.31 Million 0.00% 2.47x $159.82 Million
Boule Diagnostics AB (BOUL) $295.74 Million 7.87% 0.93x $14.38 Million
CellaVision AB (CEVI) $887.58 Million 17.25% 0.23x $311.10 Million
Clinical Laserthermia Systems AB (publ) (CLS-B) $26.09 Million -70.24% 0.12x $11.57 Million
Chordate Medical Holding AB (CMH) $25.64 Million -77.06% 0.22x $29.05K
C-Rad AB (publ) (CRAD-B) $29.82 Million -34.38% 0.50x $86.08 Million
Duearity AB (DEAR) $-2.39 Million 0.00% 0.00x $331.97K

About Promimic AB

ST:PRO Sweden Medical Devices
Market Cap
$22.97 Million
Skr213.48 Million SEK
Market Cap Rank
#24597 Global
#490 in Sweden
Share Price
Skr11.30
Change (1 day)
-3.42%
52-Week Range
Skr9.54 - Skr24.90
All Time High
Skr40.50
About

Promimic AB (publ) manufactures, markets, and sells biomaterials for improved osseointegration for orthopedic and dental implants markets. It offers HAnano surface technology that combines various properties that are known to improve osseointegration into one unique surface modification. The company was incorporated in 2004 and is based in Mölndal, Sweden.